中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共5条，第1-5条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2022
作者:  He, Libin;  Shen, Xiabo;  Liu, Yiyuan;  Gao, Lu;  Wu, Jiayi;  Yu, Chang;  Li, Guangliang;  Wang, Xiaojia;  Shao, Xiying
收藏  |  浏览/下载：41/0  |  提交时间：2022/12/23
Advanced human epidermal growth factor receptor 2-positive breast cancer (advanced HER2-positive breast cancer)  apatinib  case report  
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies 期刊论文
FRONTIERS IN PHARMACOLOGY, 2022, 卷号: 13
作者:  Wu, Xiaofan;  Yang, Hongjian;  Yu, Xingfei;  Qin, Jiang-Jiang
收藏  |  浏览/下载：51/0  |  提交时间：2022/12/22
HER2  breast cancer  targeted therapy  drug resistance  overcoming strategies  
Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2022, 卷号: 11
作者:  Zhang, Yanqiang;  Xu, Xiaoqing;  Hu, Can;  Du, Yian;  Ding, Guangyu;  Chen, Jiahui;  Zhu, Xiu;  Xu, Zhiyuan;  Wei, Qing
收藏  |  浏览/下载：37/0  |  提交时间：2022/12/23
Gastric cancer  HER2-positive  conversion therapy  
Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Fang, Zi-Ru;  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Shao, Xi-Ying;  Wang, Xiaojia
收藏  |  浏览/下载：45/0  |  提交时间：2022/12/23
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：104/0  |  提交时间：2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance